BIIB vs. QGEN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BIIB and QGEN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BIIB | QGEN |
|---|---|---|
| Company Name | Biogen Inc. | Qiagen N.V. |
| Country | United States | Netherlands |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 19.99 billion USD | 10.41 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | September 17, 1991 | June 28, 1996 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BIIB and QGEN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BIIB | QGEN |
|---|---|---|
| 5-Day Price Return | -1.98% | -2.32% |
| 13-Week Price Return | 6.21% | 9.44% |
| 26-Week Price Return | -3.04% | 21.28% |
| 52-Week Price Return | -33.44% | 6.17% |
| Month-to-Date Return | 6.53% | -2.74% |
| Year-to-Date Return | -10.83% | 7.77% |
| 10-Day Avg. Volume | 1.35M | 0.97M |
| 3-Month Avg. Volume | 1.48M | 1.40M |
| 3-Month Volatility | 30.16% | 21.77% |
| Beta | 0.10 | 0.67 |
Profitability
Return on Equity (TTM)
BIIB
9.04%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
BIIB’s Return on Equity of 9.04% is on par with the norm for the Biotechnology industry, indicating its profitability relative to shareholder equity is typical for the sector.
QGEN
10.66%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
QGEN’s Return on Equity of 10.66% is on par with the norm for the Life Sciences Tools & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
BIIB
15.31%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
BIIB’s Net Profit Margin of 15.31% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
QGEN
18.30%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
A Net Profit Margin of 18.30% places QGEN in the upper quartile for the Life Sciences Tools & Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
BIIB
20.80%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 20.80% places BIIB in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
QGEN
22.84%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
An Operating Profit Margin of 22.84% places QGEN in the upper quartile for the Life Sciences Tools & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | BIIB | QGEN |
|---|---|---|
| Return on Equity (TTM) | 9.04% | 10.66% |
| Return on Assets (TTM) | 5.43% | 6.40% |
| Net Profit Margin (TTM) | 15.31% | 18.30% |
| Operating Profit Margin (TTM) | 20.80% | 22.84% |
| Gross Profit Margin (TTM) | 75.43% | 63.73% |
Financial Strength
Current Ratio (MRQ)
BIIB
2.50
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
BIIB’s Current Ratio of 2.50 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
QGEN
1.61
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
QGEN’s Current Ratio of 1.61 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
BIIB
0.36
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
BIIB’s Debt-to-Equity Ratio of 0.36 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
QGEN
0.41
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
QGEN’s Debt-to-Equity Ratio of 0.41 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
BIIB
4.35
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
BIIB’s Interest Coverage Ratio of 4.35 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
QGEN
27.84
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
QGEN’s Interest Coverage Ratio of 27.84 is in the upper quartile for the Life Sciences Tools & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | BIIB | QGEN |
|---|---|---|
| Current Ratio (MRQ) | 2.50 | 1.61 |
| Quick Ratio (MRQ) | 1.79 | 1.19 |
| Debt-to-Equity Ratio (MRQ) | 0.36 | 0.41 |
| Interest Coverage Ratio (TTM) | 4.35 | 27.84 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BIIB
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
QGEN
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
QGEN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
BIIB
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
QGEN
0.00%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
QGEN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | BIIB | QGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
BIIB
13.27
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Biotechnology industry, BIIB’s P/E Ratio of 13.27 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
QGEN
28.51
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
QGEN’s P/E Ratio of 28.51 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
BIIB
2.03
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, BIIB’s P/S Ratio of 2.03 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
QGEN
5.22
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
QGEN’s P/S Ratio of 5.22 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
BIIB
1.04
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
BIIB’s P/B Ratio of 1.04 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
QGEN
2.97
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
QGEN’s P/B Ratio of 2.97 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | BIIB | QGEN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 13.27 | 28.51 |
| Price-to-Sales Ratio (TTM) | 2.03 | 5.22 |
| Price-to-Book Ratio (MRQ) | 1.04 | 2.97 |
| Price-to-Free Cash Flow Ratio (TTM) | 11.00 | 21.47 |